Archives

New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to [...]

PRESENTATION TITLE: Late-Breaking Oral Abstract Presentation: NOUS-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome [...]

PRESENTATION TITLE: Nouscom presentation of a Late-Breaking Abstract on Translational Phase 1b data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, at AACR 2023

PRESENTATION TITLE: Nouscom poster presentation on NOUS-PEV Personalized Neoantigen Cancer Vaccine selected for poster presentation at SITC 2022

The aim of personalized cancer vaccines is to elicit potent and tumor-specific immune responses against neoantigens specific to each patient and to establish durable immunity, while minimizing [...]